Companies › Huahui Health
4 active drug programs in 4 registered trials: 2 Phase 1, 1 Phase 3, 1 Phase 2; Oncology, Infectious disease; next expected readout Aug 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Libevitug Unclear - specific mechanism not stated in registry | – | Phase 3 | Chronic Hepatitis D Infection | Sep 2028 |
| HH-006 | – | Phase 2 | Chronic Hepatitis B Virus Infection | Feb 2028 |
| HH160 | – | Phase 1 | Solid Tumor | Aug 2027 |
| HH-009 FGF19 antagonist | FGF19 | Phase 1 | Advanced or Unresectable Hepatocellular Carcinoma (HCC) | Oct 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07623369 | HH160 | Phase 1 | Solid Tumor | Oncology | Aug 2027 |
| NCT07519330 | HH-006 | Phase 2 | Chronic Hepatitis B Virus Infection | Infectious disease | Feb 2028 |
| NCT07499544 | Libevitug | Phase 3 | Chronic Hepatitis D Infection | Infectious disease | Sep 2028 |
| NCT07547553 | HH-009 | Phase 1 | Advanced or Unresectable Hepatocellular Carcinoma (HCC) | Oncology | Oct 2028 |
Newish Biotech (Wuxi) Cantex Pharmaceuticals Lantheus Medical Imaging Jiangsu Aosaikang Pharmaceutical Henan Genuine Biotech
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.